First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Account Payables
Amounts the company owes suppliers for goods and services received.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables remains negative
Q1 FY2026 account payables was $7.5M, compared with $0 a year earlier.
Context
- Account payables amounted to 2.6% of total assets at the end of Q1 FY2026.
- Account payables increased in 1 of the last 2 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 3.11M USD
- Year-over-year change
- -17.8%
- 2-year CAGR
- +13.3%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.11M | -17.8% |
| FY2024 | 2024-12-31 | 3.79M | +56.1% |
| FY2023 | 2023-12-31 | 2.43M | — |
Account Payables vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 account payables of $7.5M is the 5th highest of the 10 companies compared; the peer median is $6.79M.
- Account payables amounts to 2.6% of total assets for TRAX, versus a peer median of 4.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $23.38M | +132.4% | — | 5.8% | |
| Mar 2026 | $14.73M | +131.8% | +8.3% | 7.4% | |
| Mar 2026 | $10.51M | +90.9% | +33.3% | 5.5% | |
| Mar 2026 | $7.52M | +22.8% | +11.6% | 2.3% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $7.5M | — | — | 2.6% |
| Sep 2026 | $6.79M | -1.9% | +77.3% | 0.9% | |
| Mar 2026 | $6.59M | +127.0% | +18.1% | 4.5% | |
| Jun 2026 | $6M | — | — | 4.7% | |
| Jun 2026 | $3.86M | +47.0% | -5.1% | 1.6% | |
CLYMClimb Bio, Inc. | Mar 2026 | $860K | +10.7% | +44.6% | 0.6% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $6.79M | +69.0% | +18.1% | 4.5% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.